Difference between revisions of "Berlin J, et al. Clin. Cancer Res. (2013) cited as Ref 606 in DOI: 10.1038/s41392-020-0110-5 (Q9869)"
Jump to navigation
Jump to search
(Created claim: Published In Name String (P102): Clin. Cancer Res., #quickstatements; #temporary_batch_1590006349955) |
(Created claim: Page(s) (P105): 258-267, #quickstatements; #temporary_batch_1590074839150) |
||
| (2 intermediate revisions by the same user not shown) | |||
| Property / Volume | |||
| + | 19 | ||
| Property / Volume: 19 / rank | |||
| + | Normal rank | ||
| Property / title | |||
| + | A randomized phase II trial of vismodegib versus placebo with FOLFOX or FOLFIRI and bevacizumab in patients with previously untreated metastatic colorectal cancer (English) | ||
| Property / title: A randomized phase II trial of vismodegib versus placebo with FOLFOX or FOLFIRI and bevacizumab in patients with previously untreated metastatic colorectal cancer (English) / rank | |||
| + | Normal rank | ||
| Property / Page(s) | |||
| + | 258-267 | ||
| Property / Page(s): 258-267 / rank | |||
| + | Normal rank | ||
Latest revision as of 15:46, 21 May 2020
Cited in: "Targeting cancer stem cell pathways for cancer therapy" in Signal Transduct Target Ther; 2020 ; 5 8
| Language | Label | Description | Also known as |
|---|---|---|---|
| English |
Berlin J, et al. Clin. Cancer Res. (2013) cited as Ref 606 in DOI: 10.1038/s41392-020-0110-5
|
Cited in: "Targeting cancer stem cell pathways for cancer therapy" in Signal Transduct Target Ther; 2020 ; 5 8
|
Statements
Berlin J
0 references
2013
0 references
Clin. Cancer Res.
0 references
19
0 references
A randomized phase II trial of vismodegib versus placebo with FOLFOX or FOLFIRI and bevacizumab in patients with previously untreated metastatic colorectal cancer (English)
0 references
258-267
0 references
